Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Financing

<< Previous

Bullboard Posts

Next >>

Comment by Red~Oneon Aug 06, 2021 5:18pm

155 Views

Post# 33667259

RE:RE:Financing

They should aready have the tax refund...."We expect to receive a third refund of approximately AUD $700,000 during Q2 this year. "

Dude51 wrote: Just a note to refute bashers insinuation. CLAS has come all this way doing lots of testing along the way. They are suppose to have 700 to 900 thousand in American Dollars from the ATO refund so that combined with the secret investor or investors we will be just fine. Thanks for the concern basher.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China